Introduction

Peeling Skin Syndrome (PSS) is a rare inherited skin condition where the outer layer of the skin peels off easily, often without pain but sometimes with redness, itching, or irritation. Because the condition is not common, there are no permanent treatments available yet. Most people rely on creams, ointments and gentle skincare routines just to keep symptoms under control. However, in this article, we are going to discuss the new medical research that is exploring investigational treatments and clinical trials that may bring hope for better care in the future.¹

Understanding of peeling skin syndrome

Genetic basis

PSS is caused by changes in specific genes that are important for keeping skin cells tightly connected and for forming a protective barrier. These genes include TGM5, CSTA, FLG2, CAST, SERPINB8, CDSN, DSG1 and SPINK5 genes, each responsible for proteins that maintain the skin barrier, adhesion, and protection.

The condition is inherited in an autosomal recessive pattern, meaning a child must get. The two faulty genes from both parents are required to develop the condition to have the disease, because if parents with only one faulty copy are usually carriers, and their children do not show symptoms, but if both are carriers, there’s a 25% chance in each pregnancy that their child will have PSS.¹

Causes of peeling skin syndrome

The main issue in PSS is a defective skin barrier due to loss of proteins that normally link skin cells together. This weak adhesion causes the outer layer of the skin (stratum corneum) to separate and peel off easily. Depending on the gene involved, this can appear as:

• Superficial peeling and blistering (hands, feet, or whole body).
• Dry scaly skin with redness and irritation.
• Thickened patches on palms or soles.
• External triggers, such as heat, sweating, and friction, can exacerbate the peeling.¹

Clinical types and their severity

Localised (Acral) type

• TGM5 gene: Causes peeling or small blisters on hands and feet. Often mild and may look like another skin condition (epidermolysis bullosa simplex)
• CSTA gene: Causes dry, scaly skin with peeling on palms and soles. Gets worse with heat, sweating, or friction

Generalised non-inflammatory type

• FLG2 gene: Leads to widespread dry and peeling skin, which usually improves with age but worsens with heat or skin injury
• CAST gene (PLACK syndrome): Causes skin peeling with white nails, thick skin patches on hands/feet, mouth sores, and nail changes
• SERPINB8 gene: Causes skin peeling from infancy, sometimes with redness or thickened patches on palms and soles

Generalised inflammatory type

• CDSN gene (PSS1): Causes widespread peeling with redness; also affects hair follicles
• DSG1 gene (SAM syndrome): Severe form with skin peeling, allergies, and metabolic issues (can be life-threatening in some cases)
• SPINK5 gene (Netherton syndrome): Causes peeling, red skin, fragile “bamboo-like” hair, and allergies due to a weak skin barrier¹

Current management approaches

Current treatments mostly focus on symptomatic care and supportive therapies by managing dryness, preventing infections, and improving comfort by applying skin softening ointments like petroleum jelly, especially after a bath when the skin is moist. It may offer some relief, but they do not target the root cause. It is not recommended to treat it with corticosteroids or vitamin A derivatives like systemic retinoids, as it is not effective and have serious side effects.¹

Need for investigational treatments

Since existing symptomatic treatments are care options which only ease the symptoms temporarily for the time being, scientists are researching different ways to treat PSS more effectively. Families living with this condition often face daily challenges, and children can experience both physical, emotional and social difficulties. This highlights the need for better, long-term solutions.

Types of investigational treatments being explored

Scientists are studying different kinds of investigational treatments:

• Topical agents: barrier repair creams or ointments, anti-inflammatory agents designed to strengthen the skin barrier or reduce inflammation²
• Systemic therapies, such as immunomodulators and retinoids, may improve skin turnover and reduce peeling²
• Gene therapy and Variation: Gene replacement, CRISPR research, all these approaches aim to replace the faulty genes responsible for the condition. Although it’s still experimental, this brings hope that it may one day offer a lasting treatment³

Recently, doctors reported a case of a woman with PSS1 caused by a new gene change. She had severe skin peeling, redness, and constant itching. Treatment with a medicine called a JAK1 inhibitor greatly improved her symptoms. This suggests that, in addition to gene therapy, targeting JAK1 could also be a promising future treatment.⁴

Clinical trials landscape

Because PSS is so rare, clinical trials are challenging. There are only a small number of patients worldwide, which makes research slow and expensive. Still, international collaborations are helping to connect patients with scientists. Some trials are testing creams or Systemic treatments, while others are still in very early stages, are exploring genetic approaches.

One interesting study looked at PSS type 1, which happens when a skin protein called corneodesmosin is missing due to a gene defect. Scientists attempted to replace this missing protein by encapsulating it in tiny protective carriers called liposomes. This treatment was tested in laboratory models.⁵

Although this research is still in its early stages and not yet available to patients, it represents the first step toward a treatment that addresses the underlying cause of the disease, rather than just its symptoms.

Challenges in advancing treatments

The biggest challenge for advancing treatment is limited funding and very small patient groups, as it's a rare disease, and ethical considerations, especially when children are involved in research or clinical studies. Despite these challenges, researchers remain hopeful, and families play an important role in raising awareness and encouraging participation in research studies.

Future directions in research

Advances in genetic testing may be a direction for treating rare conditions like PSS. A combination of new scientific tools like AI in trial design, biomarkers for monitoring, and global research networks offers hope for treatments that were once unimaginable.

Summary

Peeling Skin Syndrome (PSS) is a rare inherited condition where the outer layer of the skin peels off easily. It occurs because of changes in certain genes that normally help the skin remain strong and intact. Depending on which gene is affected, symptoms can range from mild peeling on the hands and feet to widespread redness, irritation, and thickened patches of skin.

There is no cure for this rare condition yet, and patients mostly manage temporarily with moisturisers and protective care. Researchers are now exploring new approaches, such as creams to repair the skin barrier instead of treating symptomatically and even advanced methods like gene therapy and protein replacement. Because PSS is very rare, conducting clinical trials is challenging; however, research is progressing. One recent study tested a “protein replacement therapy” for PSS type 1, where scientists delivered the missing protein into skin cells using tiny carriers called liposomes. This strengthened the skin in lab models and gave hope for future treatments.